Tiglutik

Active Ingredient(s): Riluzole
FDA Approved: * September 5, 2018
Pharm Company: * ITALFARMACO SPA
Category: Neurological Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tiglutik Overview

Riluzole (marketed as Rilutek, Teglutik and TIGLUTIK) is a drug used to treat amyotrophic lateral sclerosis. Riluzole delays the onset of ventilator-dependence or tracheostomy in selected patients and may increase survival by approximately two to three months.[2] Riluzole is available in a tablet and liquid form. The liquid formulation may be more suitable for patients with swallowing difficulties. Contents 1 Medical use 1.1 Amyotrophic lateral sclerosis 1.2 Psychiatric u...

Read more Tiglutik Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Riluzole

Recent Tiglutik Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Riluzole or a similar ingredient: (2 results)

• RILUTEK Riluzole1 discussion
• RILUZOLE 1 discussion